0000000001101687

AUTHOR

Boris Regenbogen

showing 1 related works from this author

Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.

2005

Amisulpride is a clinically effective antipsychotic drug in a broad dose range with low propensity for extrapyramidal symptoms (EPS). Daily doses and plasma levels of amisulpride were analyzed within a large-scale therapeutic drug monitoring (TDM) survey to find plasma level ranges for optimized treatment under naturalistic conditions. Data of 378 schizophrenic patients treated with amisulpride (100-1550 mg) were included (40% female). Amisulpride plasma levels were analyzed at steady state; assessment comprised improvement (CGI-I) and side-effects, particularly EPS. For detection of cut-off values regarding non-response or EPS, receiver operating characteristics (ROC) curves were applied a…

AdultMalemedicine.medical_specialtyDyskinesia Drug-InducedAdolescentmedicine.drug_classStatistics as TopicAtypical antipsychoticPharmacologyGastroenterologyExtrapyramidal symptomsInternal medicineGermanymedicineHumansAmisulprideBiological PsychiatryAgedRetrospective StudiesAged 80 and overNeurologic ExaminationPsychiatric Status Rating ScalesReceiver operating characteristicmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryDopamine antagonistMiddle Agedmedicine.diseasePsychiatry and Mental healthDose–response relationshipROC CurveSchizophreniaTherapeutic drug monitoringSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridebusinessmedicine.drugAntipsychotic AgentsJournal of psychiatric research
researchProduct